AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation

American Journal of Cancer Research

Volumn 5, Issue 5, 2015, Pages 1741-1750

  Bao, Ji Ming ^a   He, Min Yi ^b   Liu, Ya Wei ^a   Lu, Yong Jie ^c   Hong, Ying Qia ^a   Luo, Hai Hua ^a   Ren, Zhong Lu ^a   Zhao, Shan Chao ^a   Jiang, Yong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AGEs; Akt; Proliferation; Prostate cancer; RAGE; Retinoblastoma

Indexed keywords

EID: 85006208832     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end products: A review. Diabetologia 2001;44:129-46.
2. Soman S, Raju R, Sandhya VK, Advani J, Khan AA, Harsha HC, Prasad TS, Sudhakaran PR, Pandey A, Adishesha PK. A multicellular signal transduction network of AGE/RAGE signaling. J Cell Commun Signal 2013; 7: 19-23.
3. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005; 64: 92-100.
4. Lu B, Song XL, Jia LY, Song FL, Zhao SC, Jiang Y. Differential expressions of the receptor for advanced glycation end products in prostate cancer and normal prostate. Zhonghua Nan Ke Xue 2010; 16: 405-9.
5. Kim JY, Park HK, Yoon JS, Kim SJ, Kim ES, Ahn KS, Kim DS, Yoon SS, Kim BK, Lee YY. Advanced glycation end product (AGE)-induced proliferation of HEL cells via receptor for AGE-related signal pathways. Int J Oncol 2008; 33: 493-501.
6. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007; 7: 777-89.
7. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008; 14: 940-5.
8. Yaser AM, Huang Y, Zhou RR, Hu GS, Xiao MF, Huang ZB, Duan CJ, Tian W, Tang DL, Fan XG. The Role of Receptor for Advanced Glycation End Products (RAGE) in the Proliferation of Hepatocellular Carcinoma. Int J Mol Sci 2012; 13: 5982-97.
9. Radia AM, Yaser AM, Ma X, Zhang J, Yang C, Dong Q, Rong P, Ye B, Liu S, Wang W. Specific siRNA Targeting Receptor for Advanced Glycation End Products (RAGE) Decreases Proliferation in Human Breast Cancer Cell Lines. Int J Mol Sci 2013; 14: 7959-78.
10. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10: 699-703.
11. Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2000; 2: E65-7.
12. Zhang Z, Gao N, He H, Huang C, Luo J, Shi X. Vanadate activated Akt and promoted S phase entry. Mol Cell Biochem 2004; 255: 227-37.
13. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A 1990; 87: 7762-6.
14. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, Neoptolemos JP. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994; 70: 1252-7.
15. Melamed J, Einhorn JM, Ittmann MM. Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 1997; 3: 1867-72.
16. Maddison LA, Sutherland BW, Barrios RJ, Greenberg NM. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 2004; 64: 6018-25.
17. Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, Barrera J, Knudsen KE. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res 2007; 67: 6192-203.
18. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-24.
19. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 4291-6.
20. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58: 2720-3.
21. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-805.
22. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-805.
23. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008; 3: 1101-8.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2-ΔΔCt method. Methods 2001; 25: 402-8.
25. Chan JM, Latini DM, Cowan J, DuChane J, Carroll PR. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control 2005; 16: 789-97.
26. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010; 76: 1240-4.
27. Tseng CH. Prostate cancer mortality in Taiwanese men: increasing age-standardized trend in general population and increased risk in diabetic men. Ann Med 2011; 43: 142-50.
28. Liu X, Ji J, Sundquist K, Sundquist J, Hemminki K. The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer 2012; 118: 1353-61.
29. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-14.
30. Zhao CB, Bao JM, Lu YJ, Zhao T, Zhou XH, Zheng DY, Zhao SC. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res 2014; 4: 369-77.
31. Elangovan I, Thirugnanam S, Chen A, Zheng G, Bosland MC, Kajdacsy-Balla A, Gnanasekar M. Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochem Biophys Res Commun 2012; 417: 1133-8.
32. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-30.
33. Padmanabhan B, Adachi N, Kataoka K, Horikoshi M. Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6. J Biol Chem 2004; 279: 1546-52.
34. Taguchi A, Blood DC, Del Toro G, Canet A, Lee DC, Qu W, Tanii N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Inqram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signalling suppresses tumor growth and metastases. Nature 2000; 405: 354-60.
35. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001; 81: 102-13.
36. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274: 19919-24.
37. Tang CH, Keng YT, Liu JF. HMGB-1 induces cell motility and α5β1 integrin expression in human chondrosarcoma cells. Cancer Lett 2012; 322: 98-106.
38. Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, Kerkhoff C. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol 2009; 625: 73-83.
39. Riehl A, Németh J, Angel P, Hess J. The receptor RAGE: Bridging inflammation and cancer. Cell Commun Signal 2009; 7: 12.
40. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
41. Takeda A, Osaki M, Adachi K, Honjo S, Ito H. Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004; 28: 353-8.
42. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009; 9: 237-49.
43. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999; 59: 2891-7.
44. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007; 121: 1424-32.
45. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. Immuno-histochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168-71.
46. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-21.
47. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998; 95: 15587-91.
48. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM. Phosphory-lation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64: 5232-6.
49. Gao N, Zhang Z, Jiang BH, Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003; 310: 1124-32.